End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.02 USD | +3.06% | +18.58% | -96.24% |
Apr. 19 | Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product | MT |
Apr. 19 | Top Premarket Decliners | MT |
Financials (USD)
Sales 2024 * | 44.4M | Sales 2025 * | 100M | Capitalization | 985K |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | 12M | EV / Sales 2024 * | 0.02 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.01 x |
P/E ratio 2024 * |
1.29
x | P/E ratio 2025 * |
0.1
x | Employees | 44 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.55% |
1 day | +3.06% | ||
1 week | +18.58% | ||
Current month | +16.57% | ||
1 month | -89.46% | ||
3 months | -95.57% | ||
6 months | -96.44% | ||
Current year | -96.24% |
Managers | Title | Age | Since |
---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Marc Beaudoin
COO | Chief Operating Officer | - | Jan. 24 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Natan
BRD | Director/Board Member | 70 | 22-01-31 |
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 0.99 | -2.94% | 3,219,737 |
24-05-07 | 1.02 | +3.06% | 6,552,095 |
24-05-06 | 0.9897 | +17.82% | 15,306,016 |
24-05-03 | 0.84 | +0.30% | 4,994,404 |
24-05-02 | 0.8375 | -2.64% | 2,975,571 |
End-of-day quote Nasdaq, May 06, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-96.24% | 1.01M | |
+32.95% | 700B | |
+26.51% | 569B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B |
- Stock Market
- Equities
- SBFM Stock